



NSAI
Standards

Irish Standard
I.S. EN ISO 14155:2011

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2011)

I.S. EN ISO 14155:2011

Incorporating amendments/corrigenda/National Annexes issued since publication:

The National Standards Authority of Ireland (NSAI) produces the following categories of formal documents:

I.S. xxx: Irish Standard – national specification based on the consensus of an expert panel and subject to public consultation.

S.R. xxx: Standard Recommendation - recommendation based on the consensus of an expert panel and subject to public consultation.

SWIFT xxx: A rapidly developed recommendatory document based on the consensus of the participants of an NSAI workshop.

This document replaces:
EN ISO 14155:2011

<i>This document is based on:</i> EN ISO 14155:2011 EN ISO 14155:2011	<i>Published:</i> 31 October, 2011 9 February, 2011
-----------------------------------------------------------------------------	-----------------------------------------------------------

This document was published under the authority of the NSAI and comes into effect on:
31 October, 2011

ICS number:
11.100.20

NSAI
1 Swift Square,
Northwood, Santry
Dublin 9

T +353 1 807 3800
F +353 1 807 3838
E standards@nsai.ie
W NSAI.ie

Sales:
T +353 1 857 6730
F +353 1 857 6729
W standards.ie

Údarás um Chaighdeáin Náisiúnta na hÉireann

English Version

Clinical investigation of medical devices for human subjects - Good clinical practice (ISO 14155:2011)

Investigation clinique des dispositifs médicaux pour sujets
humains - Bonnes pratiques cliniques (ISO 14155:2011)

Klinische Prüfung von Medizinprodukten an Menschen -
Gute klinische Praxis (ISO 14155:2011)

This European Standard was approved by CEN on 20 September 2011.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

Management Centre: Avenue Marnix 17, B-1000 Brussels

Contents

Page

Foreword.....	3
Annex ZA (informative) Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC on Medical Devices	4
Annex ZB (informative) Relationship between this European Standard and the Essential Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices	6

Foreword

This document (EN ISO 14155:2011) has been prepared by Technical Committee ISO/TC 194 "Biological evaluation of medical devices" in collaboration with Technical Committee CEN/TC 258 "Clinical investigation of medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by April 2012, and conflicting national standards shall be withdrawn at the latest by April 2012.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 14155:2011.

This new edition contains revised Annexes ZA and ZB.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For relationship with EU Directives, see informative Annexes ZA and ZB, which are an integral part of this document.

According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

Endorsement notice

The text of ISO 14155:2011 has been approved by CEN as EN ISO 14155:2011 without any modification.

Annex ZA (informative)

Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC on Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 93/42/EEC on medical devices.

Once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this standard given in Table ZA.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations.

Table ZA.1 — Correspondence between this European Standard and Directive 93/42/EEC on medical devices

For all requirements related to clinical investigations contained in the directive and referred to in the following chart: Obligations attributed to the "sponsor" under ISO 14155 shall be incumbent, under the MDD to the manufacturer, if located in the EU/EEA/Turkey/Switzerland, and incumbent to the Authorized Representative otherwise. Both may refer to external service providers in order to fulfil their obligations.

Clause(s)/sub-clause(s) of this EN	Essential Requirements (ERs) of Directive 93/42/EEC	Qualifying remarks/Notes
Entire standard	Annex I. 6a	Partial fulfilment of the ER, as regards <ol style="list-style-type: none"> 1) the documentation of clinical investigations of medical devices used in the clinical evaluation process as referred to in Annex X.1.1¹ and 2) parts of Annex X.2 listed below.
4.1, 5.2 and 5.3	Annex X: 2.2.	ISO 14155 does not refer to a particular version of the declaration of Helsinki. The latest available version of the declaration of Helsinki must be taken into account. National/regional requirements for ethics in clinical research and for protecting the safety, wellbeing, health and rights of subjects must be observed.
5.3, 5.4, A.7	Annex X: 2.3.1	
5.3, A.3 and A.6	Annex X 2.3.2.	

¹ See MEDDEV 2.7/1, Section 6.3.

Clause(s)/sub-clause(s) of this EN	Essential Requirements (ERs) of Directive 93/42/EEC	Qualifying remarks/Notes
5.3, A.3 and A.6	Annex X: 2.3.3.	
5.3, A.5 and 8.2.5	Annex X: 2.3.4.	
6.4.1, 8.2.5 d) and 9.8	Annex X: 2.3.5.	Partial compliance: covers internal procedures of sponsor to address SAE ² -reporting requirements of the Directive.
5.5, 5.8, 6, 9.2, 9.3 and Annex B	Annex X: 2.3.6.	
7.3	Annex X: 2.3.7.	
5.4, Annex A; 5.5, Annex B; 4.7	Annex VIII, 2.2., structure/content of the documents required in the 2 nd , 3 rd and 5 th indent.	National/regional requirements for ethics in clinical research and for protecting the safety, wellbeing, health and rights of subjects must be observed.

WARNING — Other requirements and other EU Directives may be applicable to the product(s)/clinical investigations falling within the scope of this standard.

² SAE = Serious Adverse Event.

Annex ZB (informative)

Relationship between this European Standard and the Essential Requirements of EU Directive 90/385/EEC on Active Implantable Medical Devices

This European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 90/385/EEC on active implantable medical devices.

Once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this standard given in Table ZB.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations.

Table ZB.1 — Correspondence between this European Standard and Directive 90/385/EEC on active implantable medical devices

For all requirements related to clinical investigations contained in the directive and referred to in the following chart: Obligations attributed to the "sponsor" under ISO 14155 shall be incumbent, under the MDD to the manufacturer, if located in the EU/EEA/Turkey/Switzerland, and incumbent to the Authorized Representative otherwise. Both may refer to external service providers in order to fulfil their obligations.

Clause(s)/sub-clause(s) of this EN	Essential Requirements (ERs) of Directive 90/385/EEC	Qualifying remarks/Notes
Entire standard	6a	Partial fulfilment of the ER, as regards <ol style="list-style-type: none"> 1) the documentation of clinical investigations of medical devices used in the clinical evaluation process as referred to in Annex VII.1.1³ and 2) parts of Annex VII.2 listed below.
4.1, 5.2 and 5.3	Annex 7: 2.2.	ISO 14155 does not refer to a particular version of the declaration of Helsinki. The latest available version of the declaration of Helsinki must be taken into account. National/regional requirements for ethics in clinical research and for protecting the safety, wellbeing, health and rights of subjects must be observed.
5.3, 5.4, A.7	Annex 7: 2.3.1.	

³ See MEDDEV 2.7/1, Section 6.3.

Clause(s)/sub-clause(s) of this EN	Essential Requirements (ERs) of Directive 90/385/EEC	Qualifying remarks/Notes
5.3, A.3 and A.6	Annex 7: 2.3.2.	
5.3, A.3 and A.6	Annex 7: 2.3.3.	
5.3, A.5 and 8.2.5	Annex 7: 2.3.4.	
6.4.1, 8.2.5 d) and 9.8	Annex 7: 2.3.5.	Partial compliance: covers internal procedures of sponsor to address SAE ⁴ -reporting requirements of the Directive.
5.5, 5.8, 6, 9.2, 9.3 and Annex B	Annex 7: 2.3.6.	
7.3	Annex 7: 2.3.7.	
5.4, Annex A; 5.5, Annex B; 4.7	Annex 7, 2.2., structure/content of the documents required in the 2 nd , 3 rd and 5 th indent.	National/regional requirements for ethics in clinical research and for protecting the safety, wellbeing, health and rights of subjects must be observed.

WARNING — Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard.

⁴ SAE = Serious Adverse Event.

This page is intentionally left BLANK.

I.S. EN ISO 14155:2011
**INTERNATIONAL
STANDARD**

**ISO
14155**

Second edition
2011-02-01

**Clinical investigation of medical devices
for human subjects — Good clinical
practice**

*Investigation clinique des dispositifs médicaux pour sujets humains —
Bonnes pratiques cliniques*



Reference number
ISO 14155:2011(E)

© ISO 2011

PDF disclaimer

This PDF file may contain embedded typefaces. In accordance with Adobe's licensing policy, this file may be printed or viewed but shall not be edited unless the typefaces which are embedded are licensed to and installed on the computer performing the editing. In downloading this file, parties accept therein the responsibility of not infringing Adobe's licensing policy. The ISO Central Secretariat accepts no liability in this area.

Adobe is a trademark of Adobe Systems Incorporated.

Details of the software products used to create this PDF file can be found in the General Info relative to the file; the PDF-creation parameters were optimized for printing. Every care has been taken to ensure that the file is suitable for use by ISO member bodies. In the unlikely event that a problem relating to it is found, please inform the Central Secretariat at the address given below.



COPYRIGHT PROTECTED DOCUMENT

© ISO 2011

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and microfilm, without permission in writing from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Case postale 56 • CH-1211 Geneva 20
Tel. + 41 22 749 01 11
Fax + 41 22 749 09 47
E-mail copyright@iso.org
Web www.iso.org

Published in Switzerland

Contents

Page

Foreword	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	2
4 Ethical considerations	7
4.1 General	7
4.2 Improper influence or inducement	8
4.3 Compensation and additional health care	8
4.4 Responsibilities	8
4.5 Communication with the ethics committee (EC)	8
4.5.1 General	8
4.5.2 Initial EC submission	8
4.5.3 Information to be obtained from the EC	9
4.5.4 Continuing communication with the EC	9
4.5.5 Continuing information to be obtained from the EC	9
4.6 Vulnerable populations	9
4.7 Informed consent	10
4.7.1 General	10
4.7.2 Process of obtaining informed consent	10
4.7.3 Special circumstances for informed consent	10
4.7.4 Information to be provided to the subject	11
4.7.5 Informed consent signature	13
4.7.6 New information	13
5 Clinical investigation planning	14
5.1 General	14
5.2 Risk evaluation	14
5.3 Justification for the design of the clinical investigation	14
5.4 Clinical investigation plan (CIP)	14
5.5 Investigator's brochure (IB)	15
5.6 Case report forms (CRFs)	15
5.7 Monitoring plan	15
5.8 Investigation site selection	15
5.9 Agreement(s)	15
5.10 Labelling	15
5.11 Data monitoring committee (DMC)	16
6 Clinical investigation conduct	16
6.1 General	16
6.2 Investigation site initiation	16
6.3 Investigation site monitoring	16
6.4 Adverse events and device deficiencies	16
6.4.1 Adverse events	16
6.4.2 Device deficiencies	16
6.5 Clinical investigation documents and documentation	17
6.5.1 Amendments	17
6.5.2 Subject identification log	17
6.5.3 Source documents	17
6.6 Additional members of the investigation site team	17
6.7 Subject privacy and confidentiality of data	17
6.8 Document and data control	18

6.8.1	Traceability of documents and data	18
6.8.2	Recording of data	18
6.8.3	Electronic clinical data systems	18
6.9	Investigational device accountability	19
6.10	Accounting for subjects.....	19
6.11	Auditing	19
7	Suspension, termination and close-out of the clinical investigation.....	20
7.1	Suspension or premature termination of the clinical investigation	20
7.1.1	Procedure for suspension or premature termination	20
7.1.2	Procedure for resuming the clinical investigation after temporary suspension	21
7.2	Routine close-out.....	21
7.3	Clinical investigation report	21
7.4	Document retention	22
8	Responsibilities of the sponsor	22
8.1	Clinical quality assurance and quality control	22
8.2	Clinical investigation planning and conduct	23
8.2.1	Selection of clinical personnel.....	23
8.2.2	Preparation of documents and materials	23
8.2.3	Conduct of clinical investigation	24
8.2.4	Monitoring	24
8.2.5	Safety evaluation and reporting	27
8.2.6	Clinical investigation close-out.....	27
8.3	Outsourcing of duties and functions.....	28
8.4	Communication with regulatory authorities	28
9	Responsibilities of the principal investigator.....	28
9.1	General.....	28
9.2	Qualification of the principal investigator.....	28
9.3	Qualification of investigation site	29
9.4	Communication with the EC	29
9.5	Informed consent process.....	29
9.6	Compliance with the CIP.....	29
9.7	Medical care of subjects	30
9.8	Safety reporting	31
Annex A	(normative) Clinical investigation plan (CIP).....	32
Annex B	(normative) Investigator's brochure (IB).....	39
Annex C	(informative) Case report forms (CRFs)	41
Annex D	(informative) Clinical investigation report.....	43
Annex E	(informative) Essential clinical investigation documents.....	48
Annex F	(informative) Adverse event categorization	55
Bibliography	58

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 14155 was prepared by Technical Committee ISO/TC 194, *Biological evaluation of medical devices*.

This second edition cancels and replaces the first edition of ISO 14155-1:2003 and the first edition of ISO 14155-2:2003, which have been technically revised.

Clinical investigation of medical devices for human subjects — Good clinical practice

1 Scope

This International Standard addresses good clinical practice for the design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the safety or performance of medical devices for regulatory purposes.

The principles set forth in this International Standard also apply to all other clinical investigations and should be followed as far as possible, considering the nature of the clinical investigation and the requirements of national regulations.

This International Standard specifies general requirements intended to

- protect the rights, safety and well-being of human subjects,
- ensure the scientific conduct of the clinical investigation and the credibility of the clinical investigation results,
- define the responsibilities of the sponsor and principal investigator, and
- assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the conformity assessment of medical devices.

It does not apply to *in vitro* diagnostic medical devices.

NOTE Standards developed by ISO/TC 194 are intended to be applied to medical devices. Users of this International Standard will need to consider whether other standards and/or requirements also apply to the investigational device(s) under consideration.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14971:2007, *Medical devices — Application of risk management to medical devices*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

adverse device effect

ADE

adverse event related to the use of an investigational medical device

NOTE 1 This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.

NOTE 2 This definition includes any event resulting from use error or from intentional misuse of the investigational medical device.

3.2

adverse event

AE

any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device

NOTE 1 This definition includes events related to the investigational medical device or the comparator.

NOTE 2 This definition includes events related to the procedures involved.

NOTE 3 For users or other persons, this definition is restricted to events related to investigational medical devices.

3.3

audit

systematic independent examination of activities and documents related to clinical investigation to determine whether these activities were conducted, and the data recorded, analysed and accurately reported, according to the CIP, standard operating procedures, this International Standard and applicable regulatory requirements

3.4

blinding/masking

procedure in which one or more parties to the clinical investigation are kept unaware of the treatment assignment(s)

NOTE Single blinding usually refers to the subject(s) being unaware of the treatment assignment(s). Double blinding usually refers to the subject(s), investigator(s), monitor and, in some cases, centralized assessors being unaware of the treatment assignment(s).

3.5

case report forms

CRFs

set of printed, optical or electronic documents for each subject on which information to be reported to the sponsor is recorded, as required by the CIP

3.6

clinical investigation

systematic investigation in one or more human subjects, undertaken to assess the safety or performance of a medical device

NOTE "Clinical trial" or "clinical study" are synonymous with "clinical investigation".

3.7

clinical investigation plan

CIP

document that state(s) the rationale, objectives, design and proposed analysis, methodology, monitoring, conduct and record-keeping of the clinical investigation

NOTE The term “protocol” is synonymous with “CIP”. However, protocol has many different meanings, some not related to clinical investigation, and these can differ from country to country. Therefore, the term CIP is used in this International Standard.

3.8

clinical investigation report

document describing the design, execution, statistical analysis and results of a clinical investigation

3.9

clinical performance

behaviour of a medical device or response of the subject(s) to that medical device in relation to its intended use, when correctly applied to appropriate subject(s)

3.10

comparator

medical device, therapy (e.g. active control), placebo or no treatment, used in the reference group in a clinical investigation

3.11

contract research organization

CRO

person or organization contracted by the sponsor to perform one or more of the sponsor's clinical investigation-related duties and functions

3.12

coordinating investigator

investigator who is appointed by the sponsor to coordinate work in a multicentre clinical investigation

3.13

data monitoring committee

DMC

independent committee that may be established by the sponsor to assess, at intervals, the progress of the clinical investigation, the safety data or the critical performance endpoints and to recommend the sponsor whether to continue, suspend, modify, or stop the clinical investigation

NOTE Examples of DMCs are “data safety monitoring board (DSMB)” or “data safety monitoring committee (DSMC)”.

3.14

deviation

instance(s) of failure to follow, intentionally or unintentionally, the requirements of the CIP

3.15

device deficiency

inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or performance

NOTE Device deficiencies include malfunctions, use errors, and inadequate labelling.

3.16

endpoint(s)

<primary> principal indicator(s) used for assessing the primary hypothesis of a clinical investigation

3.17

endpoint(s)

<secondary> indicator(s) used for assessing the secondary hypotheses of a clinical investigation

This is a free preview. Purchase the entire publication at the link below:

[Product Page](#)

-
- [Looking for additional Standards? Visit Intertek Inform Infostore](#)
 - [Learn about LexConnect, All Jurisdictions, Standards referenced in Australian legislation](#)
-